Sugi Predict

Sugi Predict / Compounds / SCHEMBL795674

SCHEMBL795674

SCHEMBL795674

CC(C)CS(=O)(=O)N1CCC[C@@H]1c1nc(-c2nc(N)nc(N(C)c3ccccc3)n2)no1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ MAPT P10636 3/20 0.39
▸ LMNA P02545 3/20 0.39
▸ NR1H4 Q96RI1 4/20 0.35
▸ DPP4 P27487 2/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ F2 P00734 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ USP30 Q70CQ3 1/20 0.33
▸ CPT1A P50416 4/20 0.33
▸ CPT2 P23786 3/20 0.33
▸ PREP P48147 1/20 0.32
▸ DPP8 Q6V1X1 1/20 0.32
▸ DPP9 Q86TI2 1/20 0.32
▸ DPP7 Q9UHL4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL795391 0.89 SMN1; SMN2 (0.39) SMN1; SMN2MAPTLMNANR1H4DPP4
SCHEMBL796560 0.85 LMNA (0.45) SMN1; SMN2MAPTLMNAL3MBTL1NPSR1
SCHEMBL797292 0.80 HCRTR1 (0.44) CPT1ACPT2
SCHEMBL795512 0.80 HCRTR1 (0.44) CPT1ACPT2
SCHEMBL796126 0.78 LMNA (0.53) SMN1; SMN2MAPTLMNAL3MBTL1NPSR1
SCHEMBL795892 0.78 CPT1A (0.44) DPP4CPT1ACPT2PREPDPP8
SCHEMBL795246 0.78 CPT1A (0.44) DPP4CPT1ACPT2PREPDPP8
SCHEMBL15477347 0.77 GAA (0.42) SMN1; SMN2MAPTLMNAL3MBTL1NPSR1
SCHEMBL795958 0.77 DPP4 (0.44) NR1H4DPP4CPT1ACPT2
SCHEMBL794710 0.77 DPP4 (0.44) NR1H4DPP4CPT1ACPT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616465-B1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2015-11-04 — — EP disclosed
EP-2616465-B1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2015-11-04 — — EP disclosed
US-20150025057-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2015-01-22 — — US disclosed
US-20150025057-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2015-01-22 — — US disclosed
US-20150025057-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2015-01-22 — — US disclosed
US-8895733-B2 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-11-25 — — US disclosed
US-8895733-B2 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-11-25 — — US disclosed
US-8895733-B2 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-11-25 — — US disclosed
US-20140051676-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-02-20 — — US disclosed
US-20140051676-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-02-20 — — US disclosed
US-20140051676-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-02-20 — — US disclosed
EP-2616465-A1 TRIAZINE-OXADIAZOLES Novartis AG (CH) 2013-07-24 — — EP disclosed
WO-2012035023-A1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2012-03-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025057-A1 Triazine-oxadiazoles OPRK1, OPRD1, OPRL1 SMN1; SMN2 1684/4885MAPT 2602/4885LMNA 4798/4885
US-20140051676-A1 Triazine-oxadiazoles OPRK1, OPRD1, OPRL1 SMN1; SMN2 1684/4885MAPT 2602/4885LMNA 4798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.